In this episode, we explore a recent study led by Mayumi Kamata and colleagues from the Japanese Foundation for Cancer Research, investigating the effects of tumor spillage prevention in laparoscopic radical hysterectomy for early-stage cervical cancer. The study highlights the significant benefits of using preventive measures such as vaginal cuff formation or clip placement to prevent tumor spillage, which were associated with longer disease-free survival and reduced local recurrence. Tune in to hear how these findings emphasize the importance of precise surgical techniques in improving oncological outcomes for patients undergoing minimally invasive surgery.

Effects of tumor spillage prevention in laparoscopic radical hysterectomy for early-stage cervical cancer: a propensity score-matched analysis (https://doi.org/10.3802/jgo.2025.36.e22)

In this episode of the JGO Podcast, we explore a significant study comparing radical hysterectomy with primary chemoradiotherapy in patients with clinically early-stage cervical cancer and suspicious lymph nodes detected on imaging. The study, conducted by Olthof and colleagues in the Netherlands, examines recurrence-free and overall survival, treatment-related toxicity, and the implications of pre-treatment imaging. Join us as we discuss the findings and their potential impact on clinical practice in gynecologic oncology.

Radical hysterectomy or chemoradiotherapy for clinically early-stage cervical cancer with suspicious lymph nodes on imaging: a retrospective cohort study (https://doi.org/10.3802/jgo.2025.36.e16)

In this episode of the JGO Podcast, we delve into a pivotal study examining the therapeutic role of lymphadenectomy in patients with early-stage epithelial ovarian cancer. Conducted by Yang and colleagues, the study compares oncologic outcomes, including disease-free survival and overall survival, between patients who underwent lymphadenectomy and those who did not. The episode explores key findings, such as the nuanced benefits observed in patients with serous histology, and discusses the broader implications for clinical practice. We also touch on the study’s limitations and the ongoing research that could further clarify lymphadenectomy's role in this patient population.

Lymphadenectomy in clinically early epithelial ovarian cancer and survival analysis (LILAC): a Gynecologic Oncology Research Investigators Collaboration (GORILLA-3002) retrospective study (https://doi.org/10.3802/jgo.2024.35.e750)

In this episode of the JGO Podcast, we explore two Editor's Choice studies focused on ovarian cancer. First, we delve into the work of Nozaki and colleagues, who investigate the role of specific biomarkers in predicting patient responses to PARP inhibitors. Their findings challenge the conventional reliance on genomic instability scores alone and offer new insights into personalized treatment strategies. Next, we discuss the study by Yuan and colleagues, which examines how a history of breast cancer affects the response to PARP inhibitors in ovarian cancer patients with BRCA1/2 mutations. Tune in to discover how these groundbreaking studies could shape the future of ovarian cancer treatment.

Article #1: Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer (https://doi.org/10.3802/jgo.2024.35.e55)

Article #2: PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer (https://doi.org/10.3802/jgo.2024.35.e51)

In this episode of the JGO Podcast, we delve into two Editor's Choice articles focused on endometrial cancer. First, we discuss the outcomes of the East Asia subgroup in the KEYNOTE-775 trial, exploring the efficacy and safety of lenvatinib plus pembrolizumab. Then, we introduce a study that analyzed the prognostic significance of immune subtypes in copy-number high endometrial cancer, highlighting potential pathways for personalized treatment strategies.

Article #1: Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer (https://doi.org/10.3802/jgo.2024.35.e40)

Article #2: Identification of the prognostic immune subtype in copy-number high endometrial cancer (https://doi.org/10.3802/jgo.2024.35.e8)